Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
SUPN
#1407
Supernus Pharmaceuticals, Inc.
54.730
0
+0.48%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.48%
Variazione Mensile
+10.77%
Variazione di 6 mesi
+1.35%
Variazione Annuale
+1.35%
Chiusura Precedente
54.470
0
Open
54.730
0
Bid
Ask
Low
54.730
0
High
54.730
0
Volume
97
Mercati
Mercato Azionario Statunitense
Salute
SUPN
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
55.22 M
55.81 M
55.99 M
56.07 M
57.34 M
—
Valuation ratios
Enterprise value
1.69 B
1.95 B
1.72 B
1.62 B
2.59 B
7.88 B
Price to earnings ratio
28.61
27.39
29.5
27.41
-140.56
-56.25
Price to sales ratio
2.67
3.06
2.74
2.66
3.95
12.4
Price to cash flow ratio
10.07
11.77
11.15
9.47
37.21
69.6
Price to book ratio
0.46
1.95
0.45
0.43
0.64
3.48
Enterprise value to EBITDA ratio
5.5
3.57
6.84
6.56
17.69
34.66
Profitability ratios
Return on assets %
0.03
0.01
-0.01
-0
0
0
Return on equity %
0.04
0.01
-0.01
-0
0
0
Return on invested capital %
9.81
4.03
0.1
-1.89
9.66
11.91
Gross margin %
89.99
85.01
89.48
89.83
90.13
354.45
Operating margin %
19.66
12.29
-6.85
-5.06
18.71
19.1
EBITDA margin %
51.41
35
27.61
33.13
-5.62
90.12
Net margin %
21.91
8.8
-7.89
-0.7
0.06
0.27
Liquidity ratios
Quick ratio
1.98
2.16
2.26
2.43
1.47
8.32
Current ratio
2.2
2.35
2.44
2.58
1.8
9.16
Inventory turnover
0.27
0.44
0.3
0.36
0.25
1.36
Asset turnover
0.13
0.13
0.11
0.12
0.14
0.5
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.96
0.79
0.55
1.03
-1.1
1.28
EBIT per share
1.26
0.75
0.38
0.59
-0.63
1.08
EBITDA per share
1.62
1.09
0.74
0.97
-0.19
2.6
Total debt per share
—
—
—
—
—
—
Cash per share
0.57
1.24
2.07
2.55
2.7
8.56
Net current asset value per share
11.47
12.26
12.31
13.03
10.58
48.18
Tangible book value per share
6.27
7.09
7.37
8.21
5.47
28.14
Working capital per share
6.25
7.04
7.26
7.98
4.69
26.97
Book value per share
18.05
18.51
18.45
18.77
18.7
74.43
Notizie
TD Cowen alza il target di Supernus Pharmaceuticals sul rilancio di Onapgo
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch
Le azioni di Supernus Pharmaceuticals raggiungono il massimo di 52 settimane a 57,76$
Supernus Pharmaceuticals stock hits 52-week high at $57.76
Cantor Fitzgerald conferma rating Overweight su Supernus per guadagni nell’offerta
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Gli EPS di Supernus hanno mancato le aspettative per 0,48$, il fatturato supera le previsioni
Supernus earnings missed by $0.48, revenue topped estimates
Supernus affronta il test degli utili dopo lo shock alla redditività del Q3
Supernus faces earnings test after Q3 shock to profitability
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline